Registro:

Referencias:

• Mancini, T., Casanueva, F.F., Giustina, A., Hyperprolactinemia and prolactinomas (2008) Endocrinol Metab Clin North Am, 37, pp. 67-99
• Renner, U., Arzberger, T., Pagotto, U., Leimgruber, S., Uhl, E., Müller, A., Lange, M., Stalla, G.K., Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas (1998) J Clin Endocrinol Metab, 83, pp. 1368-1375
• Pivonelle, R., Matrone, C., Filippella, M., Cavallo, L.M., Di Somma, C., Cappabianca, P., Colao, A., Lombardi, G., Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment (2004) J Clin Endocrinol Metab, 89, pp. 1674-1683
• Petrossians, P., Ronci, N., Valdes Socin, H., Kalife, A., Stevenaert, A., Bloch, B., Tabarin, A., Beckers, A., ACTH silent adenoma shrinking under cabergoline (2001) Eur J Endocrinol, 144, pp. 51-57
• Pivonello, R., Ferone, D., de Herder, W.W., Kros, J.M., De Caro, M.L., Arvigo, M., Annunziato, L., Lamberts, S.W., Dopamine receptor expression and function in corticotroph pituitary tumors (2004) J Clin Endocrinol Metab, 89, pp. 2452-2462
• De Bruin, C., Hanson, J.M., Meij, B.P., Kooistra, H.S., Waaijers, A.M., Uitterlinden, P., Lamberts, S.W.J., Hofland, L.J., Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease (2008) Endocrinology, 149, pp. 4357-4366
• Greenman, Y., Tordjman, K., Osher, E., Veshchev, I., Shenkerman, G., Reider-Groswasser, I.I., Shegev, Y., Stern, N., Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth (2005) Clin Endocrinol, 63, pp. 39-44
• Lohmann, T., Trantakis, C., Biesold, M., Prothman, S., Guenzel, S., Schober, R., Paschke, R., Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline (2001) Pituitary, 4, pp. 173-178
• Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., Bruns, C., Opportunities in somatostatin research: biological, chemical and therapeutic aspects (2003) Nat Rev Drug Discov, 2, pp. 999-1017
• Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S., Rabinowitz, D., Long-acting somatostatin analog therapy of acromegaly: a meta-analysis (2005) J Clin Endocrinol Metab, 90, pp. 4465-4473
• Patel, Y.C., Greenwood, M.T., Panetta, R., Demchyshyn, L., Niznik, H., Srikant, C.B., The somatostatin receptor family (1995) Life Sci, 57, pp. 1249-1265
• Lewis, I., Bauer, W., Albert, R., Chandramouli, N., Pless, J., Weckbecker, G., Bruns, C., A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential (2003) J Med Chem, 46, pp. 2334-2344
• Schmid, H.A., Pasireotide (SOM230): development, mechanism of action and potential applications (2008) Mol Cell Endocrinol, 286, pp. 69-74
• Hofland, L.J., van der Hoek, J., Feelders, R., van Aken, M.O., van Koetsveld, P.M., Waaijers, M., Sprij-Mooij, D., Lamberts, S.W., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 (2005) Eur J Endocrinol., 152, pp. 645-654
• Batista, D.L., Zhang, X., Gejman, R., Ansell, P.J., Zhou, Y., Johnson, S.A., Swearingen, B., Klibanski, A., The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas (2006) J Clin Endocrinol Metab, 91, pp. 4482-4488
• Van der Hoek, J., Waaijers, M., van Koetsveld, P.M., Sprij-Mooij, D., Feelders, R.A., Schmid, H.A., Schoeffter, P., Hofland, L.J., Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells (2005) Am J Physiol Endocrinol Metab, 289, pp. E278-E287
• Boscaro, M., Ludlam, W.H., Atkinson, B., Glusman, J.E., Petersenn, S., Reincke, M., Snyder, P., Bertherat, J., Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial (2009) J Clin Endocrinol Metab, 94, pp. 115-122
• Rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., Patel, Y.C., Receptors for dopamine and somatostatin:formation of hetero-oligomers with enhanced functional activity (2000) Science., 288, pp. 154-157
• Saveanu, A., Lavaque, E., Gunz, G., Barlier, A., Kim, S., Taylor, J.E., Culler, M.D., Jaquet, P., Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells (2002) J Clin Endocrinol Metab, 87, pp. 5545-5552
• Greenman, Y., Melmed, S., Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors (1994) J Clin Endocrinol Metab, 78, pp. 398-403
• Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev, 13, pp. 220-240
• De Bruin, T.W., Kwekkeboom, D.J., Van't Verlaat, J.W., Reubi, J.C., Krenning, E.P., Lamberts, S.W., Croughs, R.J., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab, 75, pp. 1310-1317
• Katznelson, L., Oppenheim, D.S., Coughlin, J.F., Kliman, B., Schoenfeld, D.A., Klibanski, A., Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors (1992) J Clin Endocrinol Metab, 75, pp. 1318-1325
• Florio, T., Barbieri, F., Spaziante, R., Zona, G., Hofland, L.J., van Koetsveld, P.M., Feelders, R.A., Jaquet, P., Efficacy of a dopamine-somatostatin chimeric molecule and BIM-23A760 and in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study (2008) Endocr Relat Cancer, 15, pp. 583-596
• Newell-Price, J., Bertagna, X., Grossman, A.B., Nieman, L.K., Cushing's syndrome (2006) Lancet, 367, pp. 1605-1617
• Chambon, P., A decade of molecular biology of retinoic acid receptors (1996) FASEB J, 10, pp. 940-954
• Zang, X.K., Hoffmann, B., Tran, P.B., Graupner, G., Pfahl, M., Retinoid X receptor is an auxiliary protein of thyroid hormone and retinoic acid receptors (1992) Nature, 355, pp. 441-446
• Páez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, G.K., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108, pp. 1123-1131
• Castillo, V., Giacomini, D., Páez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Holsboer, F., Arzt, E., Retinoic acid as a novel medical therapy for Cushing's disease in dogs (2006) Endocrinology, 147, pp. 4438-4444
• Labeur, M., Refojo, D., Wölfel, B., Stalla, J., Vargas, V., Theodoropoulou, M., Buchfelder, M., Stalla, G.K., Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel Janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway (2008) J Endocrinol, 199, pp. 177-189
• Miller, M., Chen, S., Woodliff, J., Kansra, S., Curcumin (diferuloylmethane) nhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells (2008) Endocrinology, 149, pp. 4158-4167
• Vlotides, G., Siegel, E., Donangelo, I., Gutman, S., Ren, S.G., Melmed, S., Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands (2008) Cancer Res, 68, pp. 6377-6386

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------